{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:20:01Z","timestamp":1784920801031,"version":"3.55.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Eine Langzeittherapie mit Methotrexat (MTX) ist als Ausl\u00f6ser einer MTX-assoziierten lymphoproliferativen Erkrankung (MTX-LPD) bekannt. Unter einer Kombinationstherapie mit MTX und Ustekinumab kam es bei einer 58-j\u00e4hrigen Patientin mit Psoriasis vulgaris und Pityriasis rubra pilaris innerhalb von 4\u00a0Monaten zu einer generalisierten Lymphadenopathie. Die Histologie deutete zun\u00e4chst auf ein Hodgkin-Lymphom hin. Nur die Zusammenschau mit dem klinischen Hintergrund konnte die Diagnose einer MTX-LPD aufzeigen. Unseres Wissens ist dies der erste Fall einer MTX-LPD nach nur 4\u00a0Monaten Therapie.<\/jats:p>","DOI":"10.1007\/s00105-021-04804-6","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T18:02:41Z","timestamp":1617300161000},"page":"71-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Imitation eines Hodgkin-Lymphoms durch Fr\u00fchmanifestation einer Methotrexat-assoziierten lymphoproliferativen Erkrankung","Early onset of methotrexate-associated lymphoproliferative disorder mimicking Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"73","author":[{"given":"Maria Rosa","family":"Burg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"4804_CR1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/jnci\/djh313","volume":"96","author":"WH Feng","year":"2004","unstructured":"Feng\u00a0WH, Cohen\u00a0JI, Fischer\u00a0S et al (2004) Reactivation of latent Epstein-Barr virus by methotrexate: a\u00a0potential contributor to methotrexate-associated lymphomas. J\u00a0Natl Cancer Inst 96:1691\u20131702","journal-title":"J Natl Cancer Inst"},{"key":"4804_CR2","first-page":"322","volume":"34","author":"Y Hoshida","year":"2007","unstructured":"Hoshida\u00a0Y, Xu\u00a0JX, Fujita\u00a0S et\u00a0al (2007) Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76\u00a0cases in relation to methotrexate medication. J\u00a0Rheumatol 34:322\u2013331","journal-title":"J Rheumatol"},{"key":"4804_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.prp.2008.08.006","volume":"205","author":"SC Hsiao","year":"2009","unstructured":"Hsiao\u00a0SC, Ichinohasama\u00a0R, Lin\u00a0SH et al (2009) EBV-associated diffuse large B\u2011cell lymphoma in a\u00a0psoriatic treated with methotrexate. Pathol Res Pract 205:43\u201349","journal-title":"Pathol Res Pract"},{"key":"4804_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/ejh.12116","volume":"91","author":"A Ichikawa","year":"2013","unstructured":"Ichikawa\u00a0A, Arakawa\u00a0F, Kiyasu\u00a0J et al (2013) Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91:20\u201328","journal-title":"Eur J Haematol"},{"key":"4804_CR5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199305063281806","volume":"328","author":"OW Kamel","year":"1993","unstructured":"Kamel\u00a0OW, Van De Rijn\u00a0M, Weiss\u00a0LM et al (1993) Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N\u00a0Engl J Med 328:1317\u20131321","journal-title":"N Engl J Med"},{"key":"4804_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3960\/jslrt.19014","volume":"59","author":"S Momose","year":"2019","unstructured":"Momose\u00a0S, Tamaru\u00a0JI (2019) Iatrogenic immunodeficiency-associated lymphoproliferative disorders of B\u2011cell type that develop in patients receiving immunosuppressive drugs other than in the post-transplant setting. J\u00a0Clin Exp Hematop 59:48\u201355","journal-title":"J Clin Exp Hematop"},{"key":"4804_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/archderm.1997.03890430083011","volume":"133","author":"C Paul","year":"1997","unstructured":"Paul\u00a0C, Le Tourneau\u00a0A, Cayuela\u00a0JM et al (1997) Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol 133:867\u2013871","journal-title":"Arch Dermatol"},{"key":"4804_CR8","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1200\/JCO.1996.14.6.1943","volume":"14","author":"E Salloum","year":"1996","unstructured":"Salloum\u00a0E, Cooper\u00a0DL, Howe\u00a0G et\u00a0al (1996) Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J\u00a0Clin Oncol 14:1943\u20131949","journal-title":"J Clin Oncol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04804-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T09:05:03Z","timestamp":1641978303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04804-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["4804"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04804-6","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"9 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.R.\u00a0Burg und S.W.\u00a0Schneider geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}